The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Open accessAbstract
BACKGROUND: Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent that inhibits the synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9), a target for the lowering of low-density lipoprotein (LDL) cholesterol. METHODS: In this phase 1 trial, we randomly assigned healthy volunteers with an LDL cholesterol level of at least 100 mg per deciliter in a 3:1 ratio to receive a subcutaneous injection of inclisiran or placebo in either a single-ascending-dose phase (at a dose of 25, 100, 300, 500, or 800 mg) or a multiple-dose phase (125 mg weekly for four doses, 250 mg every other week for two doses, or 300 or 500 mg monthly for two doses, with or without concurrent statin therapy); each dose cohort included four to eight participants. Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol level, and exploratory lipid variables) were evaluated. RESULTS: The most common adverse events were cough, musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea. All the adverse events were mild or moderate in severity. There were no serious adverse events or discontinuations due to adverse events. There was one grade 3 elevation in the γ-glutamyltransferase level, which was considered by the investigator to be related to statin therapy. In the single-dose phase, inclisiran doses of 300 mg or more reduced the PCSK9 level (up to a least-squares mean reduction of 74.5% from baseline to day 84), and doses of 100 mg or more reduced the LDL cholesterol level (up to a least-squares mean reduction of 50.6% from baseline). Reductions in the levels of PCSK9 and LDL cholesterol were maintained at day 180 for doses of 300 mg or more. All multiple-dose regimens reduced the levels of PCSK9 (up to a least-squares mean reduction of 83.8% from baseline to day 84) and LDL cholesterol (up to a least-squares mean reduction of 59.7% from baseline to day 84). CONCLUSIONS: In this phase 1 trial, no serious adverse events were observed with inclisiran. Doses of 300 mg or more (in single or multiple doses) significantly reduced levels of PCSK9 and LDL cholesterol for at least 6 months. (Funded by Alnylam Pharmaceuticals and the Medicines Company; ClinicalTrials.gov number, NCT02314442 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inclisiran is the first siRNA approved by both US FDA and EMA for the treatment of hypercholesterolemia; the subcutaneous injection of a lipid nanoparticle formulation of the drug, which specifically binds hepatocyte asialoglycoprotein receptors, displays high potency in lowering liver PCSK9 and plasma LDL-C levels [161,162].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [161]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single subcutaneous injection of trivalent GalNAc-conjugated siRNA can achieve efficacy for >12 months22, 2324.”
From A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“However, a fibrate-induced increase in homocysteine may blunt elevation of both HDL-C and ApoA1 levels, and this effect may contribute to the smaller than estimated benefits of fenofibrate in CV outcome parameters [322].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [322]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Self-citationSafety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Self-citationTabernero, J. M., Shapiro, G. I., LoRusso, P. M., Cervantes, A. M. R., Schwartz, G. K., Weiss, G. J., Paz-Ares, L. G., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 717
Self-citationEffect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Frank-Kamenetsky, M. D., Grefhorst, A., Anderson, N. N., Racie, T., Bramlage, B., Akinc, A., Butler, D., Charissé, K., Dorkin, J. R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 645
Self-citationZhao, Z., Tuakli-Wosornu, Y., Lagace, T. A., Kinch, L. N., Grishin, N. V., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2006) · The American Journal of Human Genetics · doi:10.1086/507488 · Cited by 642
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 775
State of Gene Therapy for Monogenic Cardiovascular Diseases
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. J. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.11.003 · Cited by 16
Non‐coding RNAs to treat vascular smooth muscle cell dysfunction
Brown, S., Klimi, E., Bakker, W. A. M., Beqqali, A., & Baker, A. H. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16409 · Cited by 15
Meulebrouck, S., Merrheim, J., Quéniat, G., Bourouh, C., Derhourhi, M., Boissel, M., Yi, X., Badreddine, A., Boutry, R., Leloire, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51004-6 · Cited by 16
Artificial Intelligence to Promote Racial and Ethnic Cardiovascular Health Equity
Amponsah, D., Thamman, R., Brandt, E. J., James, C. A., Spector‐Bagdady, K., & Yong, C. M. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00745-6 · Cited by 15
Valenti, V., Noto, D., Giammanco, A., Fayer, F., Spina, R., Altieri, G. I., Ingrassia, V., Scrimali, C., Barbagallo, C. M., Brucato, F., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.09.009 · Cited by 15
Sandmark, J., Tigerström, A., Åkerud, T., Althage, M., Antonsson, T., Blaho, S., Bodin, C., Boström, J., Chen, Y., Dahlén, A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011251 · Cited by 15
Tomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
Triple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases
Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie · doi:10.1002/ange.201903618 · Cited by 15
Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias
Scognamiglio, M., Costa, D., Sorriento, A., & Claudio Napoli, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190130101108 · Cited by 16
Lenz, T., Nicol, P., Castellanos, M. I., Engel, L., Lahmann, A. L., Alexiou, C., & Joner, M. (2020) · Molecules · doi:10.3390/molecules25051029 · Cited by 16
Testa, G., Giannelli, S., Staurenghi, E., Cecci, R., Floro, L., Gamba, P., Sottero, B., & Leonarduzzi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413637 · Cited by 14
“…approved by both US FDA and EMA for the treatment of hypercholesterolemia; the subcutaneous injection of a lipid nanoparticle formulation of the drug, which specifically binds hepatocyte asialoglycoprotein receptors, displays high potency in lowering liver PCSK9 and plasma LDL-C levels [161,162].”
Morosan, P. A., Bobu, A. M., Cărăuleanu, A., Popa, R. F., Costea, C. F., Filip, C., Buzdugă, C. M., Pătrășcanu, E., Cucu, A. I., Tudosa, R. I., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110717 · Cited by 15
Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology
Mahmood, T. A., & Shapiro, M. D. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000657 · Cited by 14
Shi, S. Y., Luo, X., Yamawaki, T., Li, C.-M., Ason, B. L., & Furtado, M. B. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01517-z · Cited by 14
Yadav, P. K., Haruehanroengra, P., Irani, S., Wang, T., Ansari, A., Sheng, J., & Hussain, M. M. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101813 · Cited by 14
Zhou, W., Liang, Z., Lou, X., Wang, N., Liu, X., Li, R., & Pai, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1283922 · Cited by 14
The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
Herat, L. Y., Rudnicka, C., Okada, Y., Mochizuki, S., Schlaich, M. P., & Matthews, V. B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040884 · Cited by 14
Endothelial ARHGEF26 is an angiogenic factor promoting VEGF signalling
Zhu, Q. M., MacDonald, B. T., Mizoguchi, T., Chaffin, M. D., Leed, A., Arduini, A., Małolepsza, E., Lage, K., Kaushik, V. K., Kathiresan, S., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab344 · Cited by 14
Yu, Z., Hu, L., Sun, C., Wang, Z., Zhang, X., Wu, M., & Liu, L. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001419 · Cited by 14
Addison, M., Ranasinghe, P. D., & Webb, D. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2277330 · Cited by 14
Andersson, P. U., & den Besten, C. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788015714-00474 · Cited by 16
Cargo Receptor-Mediated ER Export in Lipoprotein Secretion and Lipid HomeostasisPreprint
Wang, X., & Chen, X. (2022) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041260 · Cited by 14
Engineered Bionanomaterials for Precision Delivery of Nucleic Acid Drugs
Bian, X., Luo, Z., Peng, B., Chen, J., Lo, P. K., Zhou, L., & Wen, Y. (2025) · Small · doi:10.1002/smll.202502667 · Cited by 16
Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools
Lotfi, M., Tambuwala, M. M., Shahcheraghi, S. H., Ayatollahi, J., Aljabali, A. A. A., Zoubi, M. S. A., Panda, P. K., Mishra, V. K., Satija, S., Charbe, N. B., et al. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220304153719 · Cited by 13
Novel therapeutic and diagnostic approaches for preeclampsia
Vatish, M., Powys, V. R., & Cerdeira, A. S. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000870 · Cited by 13
Cheng, Q., Sun, J., Zhong, H., Wang, Z., Liu, C., Zhou, S., & Deng, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393333 · Cited by 15
Bhat, O. M., Mir, R. A., Nehvi, I. B., Wani, N. A., Dar, A. H., & Zargar, M. A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101469 · Cited by 13
PCSK9 inhibition 2018: riding a new wave of coronary prevention
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Clinical Science · doi:10.1042/cs20171300 · Cited by 13
Afanasieva, O. I., Владиславович, Е. М., & Pokrovsky, S. N. (2018) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2018-8-99-109 · Cited by 15
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Averna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 13
Non-viral nucleic acid therapeutics: Revolutionizing the landscape of atherosclerotic treatment
Qu, S., Liu, R., Zhang, N., Xu, Y., Yue, X., & Dai, Z. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101514 · Cited by 14
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent
Giordano, S. A., Polimeni, A., Esposito, G., Indolfi, C., & Spaccarotella, C. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000877 · Cited by 13
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Delialis, D., Dimopoulou, M., Papaioannou, M., Kotsira, G., Maneta, E., Mavraganis, G., Loutos, C., Georgiopoulos, G. A., & Stamatelopoulos, K. S. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230412105238 · Cited by 13
PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
Pokrywka, G. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1436843 · Cited by 13
Proprotein convertase subtilisin/kexin type 9
Stoekenbroek, R. M., & Kastelein, J. J. P. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000517 · Cited by 14
RNA-based therapeutics in cardiovascular disease
Pham, T. P., Kremer, V., & Boon, R. A. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000724 · Cited by 13
Fibrillar pharmacology of functionalized nanocellulose
Wong, S., Alidori, S., Mello, B. P., Almeida, B. A., Ulmert, D., Brendel, M., Scheinberg, D. A., & McDevitt, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-020-79592-5 · Cited by 14
Novel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 13
Designer organs: The future of personalized transplantation
Buchwald, J. E., & Martins, P. N. A. (2022) · Artificial Organs · doi:10.1111/aor.14151 · Cited by 13
Long Non-coding RNA Based Therapy for Cardiovascular Disease
Quinones, N. B., Belluomo, R., Juni, R. P., & Boon, R. A. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10686-z · Cited by 12
Dutta, S., Shah, R., Singhal, S., Singh, S., Piparva, K. G., & Katoch, C. D. S. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2293201 · Cited by 12
The future of complement therapeutics
Kolev, M. V., Rao, K. N., Yeh, M. W., Parikh, A., & Deschatelets, P. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00161 · Cited by 13
Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00712-x · Cited by 12
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
Whayne, T. F. (2018) · Drugs · doi:10.1007/s40265-018-0867-9 · Cited by 12
Is There a Need to Revise Goals in the Management of Dyslipidemias?
Sinning, D., & Landmesser, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1128-6 · Cited by 12
PCSK9: from molecular biology to clinical applications
Malo, J., Parajuli, A., & Walker, S. W. (2019) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563219864379 · Cited by 12
Novel therapies for familial hypercholesterolemia
Mohamed, F., Seedat, F., & Raal, F. J. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000590 · Cited by 13
PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Kallend, D. G., Mason, J. W., Smith, P. F., Koren, M. J., Stoekenbroek, R. M., He, Y., & Wijngaard, P. L. J. (2022) · Clinical and Translational Science · doi:10.1111/cts.13391 · Cited by 12
Self-citationKuboi, Y., Suzuki, Y., Motoi, S., Matsui, C., Toritsuka, N., Nakatani, T., Tahara, K., Takahashi, Y., Ida, Y., Tomimatsu, A., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.005 · Cited by 12
Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes
Singh, A., & Cho, L. S. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23058 · Cited by 12
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12
Cheng, Z., Gao, M., Liu, Y., Yan, W., Zhang, Z., Jiao, N., & Li, C. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.10.017 · Cited by 11
Li, L., Wang, Y., Meng, J., Wang, X., Wu, X., Wo, Y., Shang, Y., & Zhang, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03003-4 · Cited by 11
Das, R. S., Datta, D., Brown, C. R., Gilbert, J. A., Chan, A., Willoughby, J. L. S., Gupta, S., Kim, M., Degaonkar, R., Racie, T., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02250 · Cited by 12
Emerging biologic therapies for hypercholesterolaemia
Pucci, G., Cicero, A. F. G., Borghi, C., & Schillaci, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1341485 · Cited by 11
Zhao, Y., Goto, M., Vaziri, N. D., Khazaeli, M., Liu, H., Farahanchi, N., Khanifar, E., Farzaneh, T., Haslett, P. A. J., Moradi, H., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000257 · Cited by 11
Sanz, D. J., Saralahti, A. K., Pekkarinen, M., Kesseli, J., Nykter, M., Rämet, M., Ojanen, M. J. T., & Pesu, M. (2021) · Liver International · doi:10.1111/liv.14993 · Cited by 11
Iluţ, S., Pîrlog, B. O., Pîrlog, R., Nutu, A. M., Văcăraș, V., & Armean, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810221 · Cited by 11
Important Aspects of siRNA Design for Optimal Efficacy In Vitro and In Vivo
Bhakta-Yadav, M. S., & Brown, T. L. (2025) · International Journal of Cell Biology · doi:10.1155/ijcb/6663816 · Cited by 11
Vivas, D., Escobar, C., Cordero, A., Fernández-Olmo, R., Oterino, A., Blanco-Echevarría, A., Botana, M., Escribano, D., Freijo, M. D. M., Losas, P. M., et al. (2024) · REC CardioClinics · doi:10.1016/j.rccl.2024.06.002 · Cited by 10
Yang, H., Li, J., Song, C., Li, H., Luo, Q., & Chen, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041743 · Cited by 11
Inhibition of Factor XI Using RBD4059
Liang, J., Nilsson, S., Wikström, J., Cao, H., Zheng, S., Xu, Q., Xu, Y., Ueckert, S., Sun, Q., Guo, C. H., et al. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.12.005 · Cited by 10
Basit, J., Ahmed, M., Singh, P., Ahsan, A., Zulfiqar, E., Iqbal, J., Fatima, M., Upreti, P., Hamza, M., & Alraies, M. C. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70039 · Cited by 10
PCSK9 in Vascular Aging and Age-Related Diseases
Tan, D., Yang, X., Yang, J., Fan, G., & Xiong, G. (2025) · Aging and Disease · doi:10.14336/ad.2024.1713 · Cited by 10
Gene therapy for cardiac arrhythmias
Bains, S., Giudicessi, J. R., Odening, K. E., & Ackerman, M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01168-5 · Cited by 10
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 11
Chien, K. R., Foo, K. S., & Witman, N. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01459-7 · Cited by 12
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 10
Gene transfer and genome editing for familial hypercholesterolemia
Canepari, C., & Cantore, A. (2023) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1140997 · Cited by 11
Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials
Olatunji, G. D., Kokori, E., Yusuf, I. A., Akinmoju, O. D., Egbunu, E. O., Muogbo, I., Lema, K. F., Kanagala, S. G., Owolabi, S., Muili, A. O., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102419 · Cited by 10
Constructing RNA Viruses for Long-Term Transcriptional Gene Silencing
Baltušnikas, J., Šatkauskas, S., & Lundstrom, K. H. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.07.015 · Cited by 10
Investigational drugs in phase II clinical trials for acute coronary syndromes
Rout, A., Sukhi, A., Chaudhary, R., Bliden, K. P., Tantry, U. S., & Gurbel, P. A. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1708324 · Cited by 11
Biotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
Zimoń, M., Huang, Y., Trasta, A., Liu, J., Liu, J. Z., Chen, C.-Y., Pepperkok, R., Klaus, B., Whelan, C. D., Sexton, D., et al. (2020) · Nature Communications · doi:10.1016/j.atherosclerosis.2020.10.593 · Cited by 10
Bellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome
Haskiah, F., Erez, D., & Khaskia, A. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.09.026 · Cited by 10
Beyond Statins: New Therapeutic Frontiers for Cardiovascular Disease
Narasimhan, S. D. (2017) · Cell · doi:10.1016/j.cell.2017.05.032 · Cited by 10
Non-coding RNAs in cardiac fibrosis: emerging biomarkers and therapeutic targets
Chen, Z., Li, C., Lin, K., Cai, H., Ruan, W., Han, J., & Rao, L. (2013) · Cardiology Journal · doi:10.5603/cj.a2017.0153 · Cited by 10
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas, F., & Ray, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2337253 · Cited by 9
A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022
Luo, Q., Tang, Z., Wu, P., Chen, Z., Fang, Z., & Luo, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218968 · Cited by 9
Targeting Liver Xor by GalNAc-siRNA Is an Effective Strategy for Hyperuricemia Therapy
Sun, H., Wang, X., Li, Y., Shen, Y., Zhang, L., Xu, Y., Liu, J., & Fan, X. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070938 · Cited by 9
The emerging role of glycans and the importance of sialylation in cardiovascular disease
Wattchow, N., Pullen, B. J., Indraratna, A. D., Nankivell, V. A., Everest‐Dass, A., Psaltis, P. J., Kolarich, D., Nicholls, S. J., Packer, N. H., & Bursill, C. A. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119172 · Cited by 9
Wu, H., Zhang, Z., Xue, Y., Guo, J., Ouyang, Z., Cao, Z., Guo, W., Zhang, Q., Wang, M., & Gu, X. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02915 · Cited by 9
Tomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Modifying organs with gene therapy and gene modulation in the age of machine perfusion
Pavan‐Guimaraes, J., & Martins, P. N. A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001007 · Cited by 9
siRNA as potential therapeutic strategy for hypertension
Tanna, S., Doshi, G., & Godad, A. P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176467 · Cited by 9
Tolksdorf, B., Heinze, J., Niemeyer, D., Röhrs, V., Berg, J., Drosten, C., & Kurreck, J. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105879 · Cited by 9
Broc, B., Varini, K., Sonnette, R., Pecqueux, B., Benoist, F., Thomas, M., Masse, M., Mechioukhi, Y., Ferracci, G., David, M., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040548 · Cited by 8
Feng, J., Xu, R., Dou, Z., Hao, Y., Xu, R., Khoso, M. A., Shi, Y., Liu, L., Sun, H., Chen, C., et al. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177228 · Cited by 9
PCSK9 inhibitors for hypercholesterolaemia
McGettigan, P., & Ferner, R. E. (2017) · BMJ · doi:10.1136/bmj.j188 · Cited by 9
Insights into a PCSK9 structural groove: a harbinger of new drugs to reduce LDL-cholesterol
Seidah, N. G. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3471 · Cited by 9
Non-coding RNAs and Ischemic Cardiovascular Diseases
Smani, T., Mayoral-González, I., Galeano-Otero, I., Gallardo, I., Rosado, J. A., Ordóñez, A., & Hmadcha, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_15 · Cited by 10
Xie, H., Yang, K., Winston‐McPherson, G. N., Stapleton, D. S., Keller, M. P., Attie, A., Smith, K. A., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112678 · Cited by 9
Khalil, I., Rahman, M. T., & Hossain, I. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.04.013 · Cited by 8
Proteomic architecture of frailty across the spectrum of cardiovascular disease
Perry, A., Zhao, S., Gajjar, P., Murthy, V. L., Lehallier, B., Miller, P., Nair, S., Neill, C., Carr, J. J., Fearon, W. F., et al. (2023) · Aging Cell · doi:10.1111/acel.13978 · Cited by 8
N-glycosylation signature and its relevance in cardiovascular immunometabolism
Svecla, M., Li‐Gao, R., Falck, D., & Bonacina, F. (2025) · Vascular Pharmacology · doi:10.1016/j.vph.2025.107474 · Cited by 8
Zhang, Y., Teng, Y., Xiao, W., Xu, B., Zhao, Y., Li, W., & Wu, L. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.009 · Cited by 9
Knöchel, J., Nilsson, C. A. M., Carlsson, B., Wernevik, L. C., Hofherr, A., Gennemark, P., Jansson‐Löfmark, R., Isaksson, R., Rydén‐Bergsten, T., Hamrén, B., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12866 · Cited by 8
Metadata
- Authors
- Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., Fernando, C., Kauffman, R. S., Kallend, D., Vaishnaw, A., & Simon, A.
- Affiliations
- Alnylam Pharmaceuticals (United States) (US)
- St George's, University of London (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-05
- Volume
- 376
- Issue
- 1
- Pages
- 41-51
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5778873
- OpenAlex
- W2555483953
- Cited by
- 768
- References
- 29
- Citations by year
- 2026: 43 · 2025: 61 · 2024: 84 · 2023: 89 · 2022: 85 · 2021: 68 · 2020: 88 · 2019: 76 · 2018: 95 · 2017: 74
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL020948)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- inclisiran, PCSK9 inhibition, RNA interference therapy, LDL cholesterol lowering, hypercholesterolemia, statin therapy, pharmacokinetics, pharmacodynamics, safety, multiple-dose regimen, single ascending dose, healthy volunteers, lipid-lowering drugs, hypertriglyceridemia, hyperuricemia
- MeSH terms
- RNAi Therapeutics, Proprotein Convertase 9, PCSK9 Inhibitors, Acetylgalactosamine, Adolescent, Adult, Aged, Anticholesteremic Agents, Female, Humans, Injections, Subcutaneous, Cholesterol, LDL, Male, Middle Aged, Single-Blind Method, RNA, Small Interfering, RNA-Induced Silencing Complex, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
